AOD-9604 has one of the stranger regulatory histories in modern medicine. The FDA declared it safe enough to put in food in 2014 — then banned it from compounding pharmacies in 2023. Now, following RFK Jr.'s February 2026 announcement that 14 previously restricted peptides will return to legal compounding status, AOD-9604 is back in the conversation. Here's what it actually does, why it was banned, and why it's generating fresh interest as a complement to GLP-1 therapy.
What Is AOD-9604?
AOD-9604 stands for Anti-Obesity Drug 9604. It's a synthetic fragment of human growth hormone — specifically the C-terminal region spanning amino acids 176 to 191 — isolated and modified by researchers at Monash University in Australia in the 1990s. The goal was simple: extract the portion of growth hormone responsible for fat metabolism while leaving behind everything else. Growth hormone is a powerful molecule, but much of what makes it clinically complicated — insulin suppression, bone and organ growth, IGF-1 elevation — comes from other regions of the molecule. AOD-9604 was engineered to be a clean lipolytic signal without the baggage.
The result is a peptide that targets fat metabolism through a distinct mechanism from GLP-1 drugs, with a safety profile supported by years of food-grade regulatory review — and a regulatory saga that's genuinely unusual.
The Strangest Regulatory Story in Peptide Medicine
In 2014, the FDA granted AOD-9604 GRAS (Generally Recognized As Safe) status — the same regulatory designation that allows ingredients like caffeine and ascorbic acid to be added to food products. The decision reflected a substantial body of safety data accumulated during clinical development, including human trials in obese adults that showed no significant adverse effects.
Yet in 2023, the FDA placed AOD-9604 on its Category 2 compounding restriction list — the category reserved for compounds the agency deemed to present safety concerns or lack evidence of clinical utility when compounded. The apparent contradiction — safe enough for your breakfast drink, not safe enough to compound as a prescription medication — generated significant pushback in the peptide medicine community.
Then on February 27, 2026, RFK Jr. announced that 14 of the 19 Category 2 peptides, including AOD-9604, would be transitioned back to Category 1 compounding status. The public comment period closes June 29, 2026, with legal access through licensed compounding pharmacies expected to resume mid-2026. The regulatory reset doesn't make AOD-9604 FDA-approved for any indication — but it restores the pathway for physicians to prescribe it through pharmaceutical-grade compounding.
How AOD-9604 Works: The Fat Metabolism Mechanism
AOD-9604 drives fat loss through two complementary mechanisms that operate independently of the hormonal pathways targeted by GLP-1 medications:
Stimulating Lipolysis
AOD-9604 activates beta-3 adrenergic receptors in adipose tissue — the same receptors stimulated during exercise-induced fat burning. Beta-3 activation triggers the release of stored triglycerides from fat cells, making fatty acids available for energy use. In animal models, this effect was pronounced in visceral adipose tissue — the metabolically active fat surrounding internal organs that is most strongly associated with cardiovascular and metabolic disease risk.
Inhibiting Lipogenesis
AOD-9604 simultaneously suppresses lipogenesis — the process by which the liver and adipose tissue convert excess calories into stored fat. By dampening both the storage pathway and the retention of existing fat stores, the compound creates a dual effect on adipose tissue mass.
Critically, AOD-9604 does not bind to IGF-1 receptors, does not suppress insulin production, and does not drive the growth-promoting effects associated with full-length growth hormone. The fragment is metabolically specific in a way that the full growth hormone molecule is not — which is precisely what the Monash researchers designed it to be.
What the Clinical Data Shows
AOD-9604 completed Phase 2b clinical trials in obese adults, where it demonstrated statistically significant fat loss compared to placebo. The results were modest by GLP-1 standards — approximately 2–3 kg of weight reduction over 12 weeks — but the mechanism and safety profile distinguished it from other options available at the time.
The clinical program ultimately stalled when the compound failed to meet the FDA's efficacy thresholds for standalone obesity drug approval. This is an important distinction: AOD-9604 was not rejected for safety reasons. It was insufficiently powerful on its own to clear the bar for a standalone obesity indication in an era before GLP-1 medications existed.
That context matters in 2026. AOD-9604 was evaluated as a monotherapy against a low bar. The question being asked now — and the one driving renewed interest in peptide medicine circles — is whether it performs meaningfully as an adjunct to GLP-1 therapy, targeting a complementary fat metabolism pathway that semaglutide and tirzepatide don't directly address.
AOD-9604 as a GLP-1 Adjunct: The Case for Stacking
GLP-1 medications work primarily through appetite suppression, slowed gastric emptying, and improved insulin signaling. They are extraordinarily effective — but they don't directly activate beta-3 adrenergic receptors or suppress lipogenesis the way AOD-9604 does. The mechanisms are complementary rather than redundant.
For GLP-1 patients who have plateaued or want to accelerate fat loss during the active weight loss phase, AOD-9604's direct lipolytic action represents a distinct intervention pathway. Reddit and biohacking forums have increasingly discussed the GLP-1 + AOD-9604 stack precisely because the compounds target different steps in the metabolic cascade:
- GLP-1 agonist: Suppresses appetite, slows gastric emptying, improves insulin sensitivity
- AOD-9604: Directly stimulates fat breakdown, inhibits new fat storage at the adipose tissue level
Whether this combination produces additive clinical benefit in well-controlled human studies remains to be formally established — but the mechanistic rationale is sound, and the safety profile of both compounds supports the combination under physician supervision.
Who Might Benefit Most From AOD-9604?
Based on the available evidence, AOD-9604 is most relevant for:
- GLP-1 patients on a weight-loss plateau: For patients who have achieved partial results on semaglutide or tirzepatide but have stalled before reaching their goal, a complementary mechanism may provide incremental benefit.
- Adults with significant visceral adiposity: AOD-9604's effects appear most pronounced in visceral fat — making it particularly interesting for patients with metabolic syndrome or abdominal obesity profiles.
- Patients seeking GH fragment benefits without growth hormone risks: Individuals who want growth hormone-adjacent effects on fat metabolism but cannot or prefer not to use growth hormone secretagogues (sermorelin, CJC-1295) due to other health factors.
- Active adults in body recomposition phases: Those who have largely achieved target weight but want targeted support for residual adiposity, particularly visceral fat, as they build lean mass.
What the Regulatory Reset Means for Access
The return of AOD-9604 to Category 1 compounding status represents a meaningful access shift. Category 1 means licensed compounding pharmacies can legally prepare the compound with a valid physician prescription. Compounded peptides sourced from licensed pharmacies must meet USP purity standards and third-party testing requirements — a significant quality improvement over the research chemical market that filled the void during the Category 2 restriction period.
For patients who explored AOD-9604 through grey-market channels before the 2023 restriction, the regulatory reset means access to verified purity, consistent dosing, and the medical supervision that proper compounding requires. For patients new to the compound, it means the conversation with a physician can now include a legally compounded option.
AOD-9604 at PepGenex
PepGenex is tracking the regulatory timeline for AOD-9604's return to Category 1 compounding status and will incorporate it into our metabolic health and weight loss protocols as legal access is confirmed. Our licensed physicians can discuss whether AOD-9604 fits your weight loss goals — including as an adjunct to existing GLP-1 therapy — and design a protocol grounded in current evidence. If you're building a comprehensive metabolic protocol or managing a GLP-1 plateau, this is a conversation worth having now.
This content is for informational purposes only and does not constitute medical advice. Consult a licensed physician before starting any peptide therapy.